CEL SCI CORP (CVM)

Biological Products, (No Diagnostic Substances) · market cap $30M · as of 2026-10-11

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

CEL SCI CORP (NYSE American: CVM) is a micro-cap immunotherapy developer (market cap ~$16M, ~8.49M shares, ~$1.94 per share). Our database lists one pipeline program, LI, in Phase 3 for squamous cell carcinoma of the oral cavity. Our coverage of this name is limited: no catalysts are in our calendar, and mechanism, employee count, ownership and dilution history are not in our coverage. The setup in our data is dominated by a very short reported cash runway.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
LI	Phase 3	Squamous Cell Carcinoma of the Oral Cavity

Price & technical context

3-month

-7.2%

6-month

-19.0%

12-month

-80.1%

52-wk range

$0.97–$7.67

vs 50-day MA

-17.1%

vs 200-day MA

-43.1%

Realized vol

111.4%

Max drawdown

-96.9%

Daily closes through 2026-11-03. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for CVM (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.